Related Experiment Video
Updated: Nov 26, 2025
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Measuring factor VIII activity in samples from patients treated with N8-GP (Esperoct® ; turoctocog alfa pegol) during
Judi Møss1, Wan Hui Ong Clausen1, Mirella Ezban2
1Novo Nordisk A/S, Søborg, Denmark.
Abstract:
FVIII activity in samples taken at various time points from 21 patients treated with N8-GP (Esperoct® ; turoctocog alfa pegol) during the pathfinder clinical trial programme was assessed and compared using different assay methods. FVIII activity measurements in samples from patients treated with N8-GP were similar using chromogenic assays, regardless of calibration method or kit/analyser combination. FVIII activity measurements using one-stage aPTT-based assays were slightly lower when calibrated using normal human plasma (NHP) compared with a product-specific standard; this difference may be partially attributable to differences in the aPTT reagent/analyser combinations used to perform the measurements. Overall, these results confirm the accuracy of FVIII activity measurements using N8-GP-treated patient samples and routine clinical laboratory methods with NHP calibration.
Insights
Assessing factor VIII (FVIII) activity in patients treated with N8-GP (turoctocog alfa pegol) showed consistent results across various laboratory methods. Normal human plasma calibration is confirmed as accurate for routine clinical testing.
Area of Science:
- Hematology
- Clinical Chemistry
- Pharmacokinetics
Background:
- This study evaluated factor VIII (FVIII) activity measurements in patients receiving N8-GP (turoctocog alfa pegol) during the Pathfinder clinical trial.
- The assessment utilized samples collected at multiple time points to ensure comprehensive data.
- Comparison of different assay methods was performed to validate measurement accuracy.
Discussion:
- Chromogenic assays demonstrated consistent FVIII activity measurements for N8-GP treated samples, irrespective of calibration or assay kit.
- One-stage aPTT-based assays showed slightly lower FVIII activity when calibrated with normal human plasma (NHP) compared to a product-specific standard.
- Discrepancies in aPTT assays may be attributed to variations in reagent and analyzer combinations.
Key Insights:
- FVIII activity measurements in N8-GP treated patients are reliable across various chromogenic assay platforms.
- Normal human plasma (NHP) calibration is suitable for routine clinical laboratory assessment of FVIII activity in patients on N8-GP.
- Understanding assay-specific calibration effects is crucial for accurate FVIII activity monitoring.
Outlook:
- Further validation of N8-GP activity assays with diverse laboratory systems is warranted.
- Standardization of assay calibration methods for extended half-life FVIII products is recommended.
- Continued monitoring of FVIII activity will support long-term patient management and treatment efficacy.
